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Abstract: Angiogenesis,  formation  of  new  blood  vessels,  is  a  complex  but  critical  phenomenon.  In 
particular,  it  is  regulated by different  angiogenic  factors.  Nitric  oxide  (NO) is  also a  very well  known 
biological mediator involved in vascular physiology. This study focuses on relationships between the effect 
of  angiogenin,  a  major  angiogenic  factor,  and  extracellular  NO  release.  NO concentration  was  sensed 
electrochemically  using  a  fibronectin  coated  multiple  microelectrode  array.  Angiogenin  was  shown  to 
increase NO levels, thus triggering nitric oxide synthase (NOS) activity. Angiogenin reactive pathway being 
very complex, we have used various selective inhibitors of angiogenin to investigate the mechanism leading 
to NO production. Neomycin, an antibiotic blocking nuclear translocation, inhibited angiogenin effect on 
NOS. This result demonstrates that angiogenin activates NOS by interacting with the cell nucleus.
Keywords: angiogenesis,  electrochemical  sensing,  nitric  oxide  synthase,  biomeasurements,  stem 
cells, angiogenin
Introduction
Angiogenesis,  formation  of  new  blood 
vessels,  is  critical  factor  in  much pathology 
like  chronic  wounds  (Harding  et  al.,  2002) 
and  rheumatoid  arthritis  (Walsh,  1999).  In 
particular,  it  has  been  proven  that  tumours 
release angiogenic factors in order to support 
their  growth,  carcinogenesis  being  strongly 
dependent on blood supply (Carmeliet et al., 
2000).  However,  angiogenesis  is  a  rather 
complex  biological  phenomenon  that  is 
dependent on the extra cellular matrix (Clark, 
1995),  mechanical  or  shear  stress  (Baum et 
al.,  2004)  and  biochemical  factors.  For 
example,  some  growth  factors  like  vascular 
endothelial  growth  factors  are  known  to 
promote endothelial growth and angiogenesis 
(Ferrara, 2001). This biological phenomenon 
involves the activation of blood vessel cells to 
an  altered  state  as  a  response to  a  complex 
balance of competing stimuli. Investigating its 
biochemistry  therefore  seems  the  most 
obvious  way  to  understand  and  modulate 
angiogenesis.
In  this  study,  we  are  focusing  on  an 
angiogenic protein, angiogenin. Angiogenin is 
a 123 amino acids long single-chain protein of 
about 14,400 kDa (Gao and Xu, 2008). This 
molecule  is  a  requirement  for  cell 
proliferation,  even  for  angiogenesis  induced 
by  other  angiogenic  factors,  like  fibroblast 
growth factors or endothelial  growth factors 
(Kishimoto et al., 2005). In particular, it has 
been  reported  that  nuclear  translocation  of 
angiogenin,  e.g.  angiogenin  entering  cell 
nucleus, is a critical step for the biochemical 
cascade triggering angiogenesis (Kishimoto et 
al., 2005). Furthermore, angiogenin is known 
to have several effects on cells (Gao and Xu, 
2008): 
(i) it  can  bind  to  the  actin  receptors 
and cleave the extracellular matrix, 
thus allowing cell migration (Hu et 
al., 1994), 
(ii) it has an RNase activity (Russo et 
al., 1994), 
(iii) it  can  bind  to  cell  membrane 
receptors  and  trigger  an 
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intracellular  biochemical  cascade 
(probably  via  signal-associated 
kinases ERK1/2 (Liu et al., 2001) 
and  B/Akt  (Kim et  al.,  2008)  or 
via  the  phosphorylation  of  stress 
associated kinase SAPK/JNK (Xu 
et al., 2001)),
(iv) it  can  enter  the  cell  nucleus  and 
interact  with  ribonucleotides 
(nuclear  translocation)  (Xu et  al., 
2001). 
Because of these numerous  sites and modes 
of  action,  the  physiology  of  angiogenin  is 
quite unclear. 
NO  is  produced  by  nitric  oxide  synthase 
(NOS,  in  our  case  the  endothelial  NOS, 
eNOS) from L-arginine (Palmer et al. 1988). 
NO is  a  biological  transmitter  mediating  in 
particular  vasodilation  and  angiogenesis 
(Fukumura et  al.,  1998).  NO  is  therefore 
implied in a wide range of heart and vascular 
diseases. It has been demonstrated that nitric 
oxide  (NO)  plays  a  central  role  in 
angiogenesis  (Fukumura et  al.,  1998)  by 
triggering  the  proliferation  of  angiogenic 
growth  factors  and  the  differentiation  of 
endothelial  cells  into  vascular  tube  cells 
(Babaei  et  al.,  1998).  Ziche et  al.  have also 
shown that  NO can  lead  to  DNA synthesis 
and migration of coronary endothelial cells as 
many other  angiogenic  factors  (Ziche  et  al., 
1993  and  1994).  In  addition,  NO may  also 
promote angiogenesis through its endothelial 
antiapoptotic  properties  (Chavakis  et  al., 
2002):  angiogenesis  is  mainly  based  on 
proliferation of endothelial cells and therefore 
on inhibition of their apoptosis. 
As  a  consequence,  NO  is  a  key  factor  in 
angiogenesis. The purpose of this study is to 
investigate  relationships  between angiogenin 
and extracellular NO release. Measurement of 
NO was performed electrochemically, using a 
multiple  microelectrode  array  (MMA) 
developed at Imperial College London (UK) 
(Patel  et  al.,  2008).  Electrochemical  sensors 
are  attractive  devices  for  biomeasurements 
because  of  robustness,  linear  response  to 
concentration,  ease  of  production  and 
miniaturization.  We  have  already 
demonstrated the utility of the MMA for NO 
sensing in fibroblast cells (Patel et al., 2008). 
To  improve  biocompatibility,  the  surface  of 
the  MMA  was  coated  with  fibronectin,  an 
extra  cellular  matrix  protein.  Fibronectin  is 
known to promote adequate cell adhesion and 
growth, and we have shown that it  does not 
interfere  with  electrochemical  measurements 
(Trouillon et al., 2009). 
Firstly, (i)  human  umbilical  vascular 
endothelila cells (HUVEC) and (ii) embryonic 
stem  cells  (ESC)  derived  endothelial  cells 
were  grown  directly  on  the  sensor  (2x104 
cells.cm-1 to promote angiogenesis (Hu et al., 
1997)), angiogenin was added and NO levels 
were monitored. Then, several inhibitors were 
used  to  study  more  deeply  the  effect  of 
angiogenin  on  NO:  L-NAME,  RNase 
inhibitor  and  neomycin.  L-NAME,  an 
analogue of L-arginine, the eNOS substrate, is 
a competitive eNOS inhibitor, and blocks NO 
production  (Rees  et  al.,  1990).  RNase 
inhibitor  (RI)  and  neomycin  inhibit 
selectively  different  reaction  pathways  of 
angiogenin. RI binds to the angiogenin RNase 
site with very high affinity (Ki ~ 10-13 – 10-16 
M) (Chen et al., 1997). In addition, neomycin 
is an antibiotic used in cancer treatment. It is 
known  to  block  angiogenin  nuclear 
translocation (Hu, 1998).
Examining the release of NO in the presence 
of these inhibitors should therefore elucidate 
the relationships between NO and angiogenin 
and identify the mode and site of action.
Materials and methods
Materials
All  the  chemicals  used  in  this  study  were 
purchased  from  Sigma,  unless  stated 
otherwise,  and  were  used  without  further 
purification. Deionized water purified through 
a  Millipore  system was  used  throughout  all 
the experiments.  Angiogenin was purified as 
previously  described  (Jang  et  al.,  2004). RI 
was purchased from Intron Biotechnology. 
Characterization of sensors
The  MMA was  calibrated  using  aliquots  of 
authentic  solution of NO. This solution was 
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prepared  according  to  Feelisch  and  has 
already been described elsewhere (Patel et al., 
2008). Background current was measured in 
degassed phosphate buffered saline (PBS, pH 
=  7.4)  by  differential  pulse  voltammetry 
(DPV),  versus  the  MMA  pseudo-gold 
reference. NO was then added to reach a final 
concentration of 75 μM. DPV was performed 
again to identify the peak potential.
Cell culture
HUVEC were purchased from Clonetics (San 
Diego,  USA)  and  cultivated  in  EBM-2 
medium (Clonetics)  on gelatin coated 75 ml 
flasks, at 37°C, 95% O2, 5% CO2. Cells from 
passage 6 to 9 were used.
ESC-derived endothelial  cells  were prepared 
by mechanical isolation and cell sorting (Cho 
et al., 2007).
Modification  and  preparation  of  the 
sensors
The  MMA  were  modified  using  a  sylgard 
(Dow Corning) custom-made reaction cell to 
allow deposition of a 500 μl volume on the 
sensor. A lid made from a Petri dish was also 
fitted on the cell to minimise evaporation.
Prior to any experiment, biological debris was 
removed using trypsin solution. Trypsin was 
deposited  into  the  cell  and  incubated  it  at 
37°C  for  one  hour.  They  were  then  rinsed 
with  70%  ethanol  followed  by  water.  The 
gold  electrodes  were  electrochemically 
cleaned by performing cyclic voltammograms 
between 1 V and -0.8 V at 0.5 V.s-1 in 0.1 M 
sulphuric  acid  until  stability  of  the  graphs. 
The electrodes potential was then held at –0.6 
V to reduce gold oxides.
The  sensor  was  then  sterilized  with  70% 
ethanol  and  UV  light  and  rinsed  with  PBS 
(pH = 7.4). 100 μl of human fibronectin (20 
μg.ml-1,  in  DMEM)  was  deposited  on  the 
sensor  and  let  to  dry.  The  excess  of 
fibronectin was rinsed with PBS.
Electrochemical measurements
Cells  were  harvested  using  trypsin  and 
counted  with  a  cytometer  and  Trypan  blue. 
1000  cells  were  suspended  in  500  μl  of 
EBM-2 medium and deposited on the sensor. 
The  chip  was  then  incubated  for  at  least  2 
hours.
A DPV was then recorded between 0 V and 
1.5 V vs Ag/AgCl.
2  μl  of  bovine  angiogenin  (5.26  mg.ml-1  in 
deionized water) were added with the relevant 
inhibitor  if  required  (protocol  described 
below)  to  reach  a  final  concentration  of  21 
μg.ml-1.  The  MMA  was  placed  in  the 
incubator for one hour and another DPV was 
recorded.
Inhibitors
For  the  L-NAME  study,  the  cells  were 
maintained in culture medium containing 100 
μM L-NAME during at least one hour before 
any measurement.
Similarly,  in the neomycin  setup, cells  were 
cultivated  for  at  least  one  hour  in  medium 
containing  50  μM  neomycin  before  any 
measurement.
The  RNase inhibitor  was mixed  with 
angiogenin (1:2 mass ratio) and incubated at 
37°C  for  one  hour.  This mixture  was then 
added  to  the  cell  medium  to  reach  a  final 
angiogenin  concentration  of  21  μg.ml-1 and 
incubated for 1 hour.
Data processing
The  DPV  results  were  processed  by 
normalizing  the  peak  current  obtained  after 
angiogenin  injection  by  the  peak  current 
measured before injection. This normalization 
guaranteed consistency between the different 
measurements  by  minimizing  the  effect  of 
variations  in  size,  background  species, 
heterogeneity  in  cell  population. The results 
obtained  for  each  experimental  condition 
were then averaged, and the means compared 
using Student’s t-tests.
Results
Measurement  of  nitric  oxide  and  other 
nitrous compounds
Fig.1  shows  curves  obtained  for  various 
dissolved  NO  solutions.  We  notice  a  sharp 
peak  at  0.6V.  This  peak  is  due  to  NO 
oxidation  and  increases  with  NO 
concentration.
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Figure  1:  Differential  pulse voltammograms in PBS, 
pH = 7.4, with increasing concentration of nitric oxide
Figure  2:  Differential  pulse  voltammograms  in 
EBM-2  medium  in  presence  of  HUVEC,  with 
angiogenin,  in presence (  )  or absence of L-NAME 
(),  and  control  without  angiogenin  and  L-NAME 
(∙∙∙∙∙)  (top);  Results  for  the  differential  pulse 
voltammograms  performed  in  EBM-2  medium  in 
presence of HUVEC, with angiogenin, in presence or 
absence of L-NAME, and control without angiogenin 
and L-NAME ( n ≥ 17, ***: p <  0.001) (bottom)
Effect of angiogenin 
Fig.2 displays  typical  voltammograms 
obtained from HUVEC measurements.
Results for control setup and after angiogenin 
addition, in presence or absence of L-NAME, 
are  also presented.  We see similar  peaks  to 
the ones obtained for pure NO solutions.  In 
particular, we see that if L-NAME is present, 
the  response  is  very  similar  to  the  one 
measured in the control experiment. However, 
if only angiogenin is added to the medium, we 
notice an increase in peak magnitude. These 
results  are  summarized  on  Fig.2,  which 
presents the ratio of the peak magnitude after 
and before addition of angiogenin. There is a 
significant  increase  in  peak  height  if  only 
angiogenin is present (+ 21%, p < 0.0001, n ≥ 
17). However, if the HUVEC were previously 
incubated 100 μM L-NAME, we do not see 
any significant change in peak magnitude (p > 
0.8, n ≥ 17). 
As a control, the same protocol was applied to 
stem cell derived endothelial cells (Fig.3). We 
obtained  exactly  similar  results,  angiogenin 
leading to an increase in the peak current (+22 
%,  p<0.0001,  n  ≥  18),  and  L-NAME 
inhibiting this increase.
Figure  3:  :  Results  for  the  differential  pulse 
voltammograms  performed  in  EBM-2  medium  in 
presence  of  ESC derived  endothelial  cells,  with 
angiogenin,  in presence or absence of L-NAME, and 
controls  without  angiogenin  and  L-NAME,  and  with 
L-NAME only ( n ≥ 18, ***: p <  0.001)
Effect of inhibitors
To understand the physiological pathway of 
angiogenin,  several  selective  inhibitors  have 
been used in the same kind of experiment 
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a) RNase inhibitor
Fig.4 shows the statistical results obtained for 
addition of angiogenin in presence or absence 
of RNase inhibitor (RI). Angiogenin alone led 
to an increase in magnitude of 22% (p<0.001, 
n ≥ 10) and addition of a mixture of RI and 
angiogenin increased the peak magnitude by 
17%  (p<0.001,  n  ≥  10).  The  increases 
observed  for  both  treatments  are  not 
statistically significantly different (p > 0.45, n 
≥10). 
Figure  4:  Results  for  the  differential  pulse 
voltammograms  performed  in  EBM-2  medium  in 
presence of HUVEC, with angiogenin, in presence or 
absence of RI, and control without angiogenin and with 
RI ( n ≥ 10, ***: p <  0.001)
Figure  5:  Results  for  the  differential  pulse 
voltammograms  performed  in  EBM-2  medium  in 
presence of HUVEC, with angiogenin, in presence or 
absence of neomycin, and control without angiogenin 
and with neomycin ( n ≥ 10, ***: p <  0.001)
b) Neomycin
Fig.5 shows  the  results  obtained  for  this 
experiment.  Again,  if  we add angiogenin  to 
the cell medium, we see an increase in current 
peak (+ 27%, p < 0.001, n ≥ 10). However, if 
the  cells  were  previously  incubated  with 
neomycin, no significant increase is measured 
(p  <  0.55,  n  ≥  10).  Neomycin  inhibits  the 
angiogenin induced increase in peak current
Discussion
Effect  of  angiogenin  on  nitric  oxide 
synthase activity
We have shown that adding angiogenin to cell 
medium  led  to  a  higher  current  peak.  In 
addition, this peak is very similar to the one 
obtained previously in pure NO solutions and 
is  expected  to be due to  an increase  in  NO 
concentration.  This  NO  is  expected  to  be 
produced by the HUVEC, NOS activity being 
probably  triggered  by  angiogenin.  This 
assertion  was  confirmed  by  the  L-NAME 
tests. As an analogue of L-arginine, L-NAME 
is  known to  inhibit  competitively  NOS and 
therefore  NO  production.  By  adding  L-
NAME to our setup, NOS in our population 
of  HUVEC  is  inhibited  and  no  current 
increase  is  observed.  This  shows  that  this 
increase  in  peak  current  was  due  to  NOS 
activity  and  that  the  peaks  we  measure  are 
due  to  NO  oxidation.  Furthermore,  these 
experiments  show  that  angiogenin  triggers 
NOS  activity  and  leads  to  increases  in 
extracellular NO.
The  same  results  were  obtained  when  the 
same experiment was carried out in stem cell 
derived endothelial cells as a control showing 
that angiogenin induced NOS activation is a 
general feature of endothelial cells. 
Figure 4: A hypothetical scheme for the mechanism of 
action of angiogenin modified from Kim et al. (2008)
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Physiological pathway of angiogenin
The  physiological  pathway  leading  to  NOS 
activation  was  studied  using  2 angiogenin 
inhibitors:  RI and neomycin.  We do not see 
any effect  of  RI,  indicating  that  angiogenin 
induced  eNOS  activity  does  not  depend  on 
the  RNase activity. However,  neomycin 
completely  inhibits  the  NO  increase. 
Neomycin blocking nuclear translocation, this 
result  shows that eNOS is activated through 
angiogenin  interactions  with cell  nucleus. A 
modification  of  hypothetical  scheme for  the 
mechanism of action of angiogenin is shown 
in Fig. 6. This conclusion has to be related to 
the  fact  that  nuclear  translocation  of 
angiogenin  is  a  general  requirement  for 
angiogenesis (Kishimoto et al., 2005).
Conclusion
We have demonstrated that angiogenin leads 
to  enhanced  release  of  NO.  Interaction  of 
angiogenin with the cell nucleus is a critical 
requirement  for  this  angiogenin  induced 
eNOS  activity,  which  tends  to  prove  that 
nuclear translocation of angiogenin is a major 
event  in  angiogenesis.  Selective  inhibitors 
demonstrate  that  nuclear  translocation  is 
required for angiogenin mediated NO release.
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